Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.78

0.0%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2948)	6/21/2010 11:18:07 AM
From: mlkr	of 3722

ISTA:TEL AVIV (MarketWatch) -- Ista Pharmaceuticals Inc., /quotes/comstock/15*!ista/quotes/nls/ista (ISTA 2.71, -0.01, -0.37%) the Irvine, Calif., producer of ophthalmic drugs, received clearance from the U.S. Food and Drug Administration to market Bepreve, generically bepotastine besilate, to treat itching in the eye associated with allergic conjunctivitis for patients age 2 and older. In a statement late on Tuesday, Ista said it now expected to be able to recognize revenue from the drug this year. It increased its estimate of full-year 2009 revenue to a range of $104 million to $107 million, while it reiterated that it will be operating-earnings neutral for the year. Early in August, the company pegged revenue for 2009 at $95 million to $100 million.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next